论文部分内容阅读
观察131I治疗青少年分化型甲状腺癌(DTC)对外周血的影响。31例青少年(≤20岁,随访时间6～18个月)DTC患者接受131I治疗后(剂量2.96～11.1GBq),利用全自动血液分析仪,对131I治疗前、治疗后1个月、治疗后6个月及随访末白细胞(WBC)、中性粒细胞(Neut)、红细胞(RBC)、血红蛋白(HBG)及血小板(PLT)进行检测,对131I治疗前后结果进行对比分析。服用131I治疗后1个月,患者PLT下降(P<0.01),WBC下降(P<0.05),RBC下降(P<0.05)、HBG降低(P<0.05),Neut未见明显变化(P>0.05);治疗后6个月患者WBC、Neut、RBC、HBG及PLT均接近治疗前水平(P>0.05),大剂量组(7.4～11.1GBq)患者随访末外周血各指标均与首次治疗前水平无差异(P>0.05)。131I治疗青少年DTC,对外周血有一过性影响,是一种安全的治疗手段。
To observe the effect of 131I treatment on adolescent differentiated thyroid cancer (DTC) on peripheral blood. Thirty-one adolescents (≤20 years of age, followed up for 6 to 18 months) received 131I (dose range, 2.96-11.1GBq) after DTC treatment. Before treatment with 131I, 1 month after treatment, The WBC, Neut, RBC, PLG and PLT were measured at 6 months and at the end of follow-up. The results of 131I treatment before and after treatment were compared and analyzed. (P <0.01), WBC decreased (P <0.05), RBC decreased (P <0.05), HBG decreased (P <0.05), Neut had no significant change (P> 0.05) ). The WBC, Neut, RBC, HBG and PLT of patients at 6 months after treatment were close to those before treatment (P> 0.05). The indexes of peripheral blood in the high-dose group (7.4-11.1GBq) No difference (P> 0.05). 131I treatment of adolescents DTC, had a transient impact on peripheral blood, is a safe treatment.